#United States #Medical Devices #Biocomposites #Keele #SYNICEM

Introduction to SYNICEM™ Spacers

Biocomposites, a renowned player in the global medical device arena, has announced the launch of its cutting-edge SYNICEM™ antibiotic-loaded preformed spacers across the United States. This innovative product is engineered to enhance infection management during complex joint revision surgeries, specifically targeting hip, knee, and shoulder procedures. The SYNICEM™ spacers are not only designed for effectiveness but also for ease of use, ensuring they quickly meet the needs of healthcare professionals.

Benefits of SYNICEM™ Spacers

The SYNICEM™ spacers are notable for their ability to maintain a sustained local concentration of gentamicin, an essential antibiotic. This capability is crucial because it preserves the articular space, limb length, and overall joint stability during two-stage revision processes. Unlike traditional molds or handmade spacers, which can be time-consuming and contain inherent variability, SYNICEM™ spacers are precision-engineered. They are pre-sterilized and can be utilized within a minute, significantly cutting down on operative time and eliminating mechanical risks associated with other methods.

Moreover, the SYNICEM™ product line includes various sizes, designs, and specific geometrical options, such as the Charnley and Müller hip spacer designs, and distinct configurations for knee procedures (left and right designs). This adaptability allows surgeons to tailor interventions based on individual patient needs.

Over Two Decades of Proven Efficacy

For more than 20 years, SYNICEM™ spacers have been effectively utilized in over 70 countries, helping medical professionals address complex infections in joint surgeries. Michael Harris, the CEO of Biocomposites, expressed enthusiasm regarding the U.S. launch, emphasizing the spacers' role in offering smoother and more reliable surgical results. The consistent structure and local antibiotic delivery system make SYNICEM™ spacers a preferred choice for surgeons, enhancing their capability to handle difficult cases involving infections.

Biocomposites: Pioneering Infection Management

Founded and headquartered in Keele, England, Biocomposites specializes in manufacturing innovative products for infection management in bone and soft tissue. With an impactful presence across Europe, South America, the USA, Canada, China, and India, the company is recognized for its development of advanced calcium compounds and bone cements. Their offerings help manage bone regeneration and infection risk across various medical fields, including orthopedics, podiatry, and sports medicine. Annually, Biocomposites' products facilitate over a million surgical procedures in more than 100 countries, highlighting their extensive market reach and reliability.

Conclusion

The introduction of SYNICEM™ spacers marks a significant milestone in the U.S. market for Biocomposites. Their unique design approach not only speeds up surgical interventions but aids in effective infection control, showcasing the potential of modern medical technology. Surgeons seeking a dependable and efficient tool for joint revision procedures will find SYNICEM™ spacers to be an invaluable addition to their surgical toolkit.

For more information about Biocomposites and their innovative products, visit biocomposites.com.